Abstract
The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.
Original language | English (US) |
---|---|
Pages (from-to) | 272-274 |
Number of pages | 3 |
Journal | Journal of Nuclear Medicine Technology |
Volume | 25 |
Issue number | 4 |
State | Published - Dec 1997 |
Externally published | Yes |
Keywords
- Fluorine-18-fluorodeoxyglucose
- Gamma camera
- Myocardial viability
- Positron emissions
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging